NASDAQ:HRTX Heron Therapeutics (HRTX) Stock Price, News & Analysis $0.43 0.00 (-1.03%) Closing price 04:00 PM EasternExtended Trading$0.44 +0.00 (+0.48%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Heron Therapeutics Stock (NASDAQ:HRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Heron Therapeutics alerts:Sign Up Key Stats Today's Range$0.42▼$0.4550-Day Range$0.38▼$1.3152-Week Range$0.38▼$2.28Volume2.63 million shsAverage Volume3.44 million shsMarket Capitalization$82.13 millionP/E RatioN/ADividend YieldN/APrice Target$2.50Consensus RatingHold Company Overview Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids. Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S. Food and Drug Administration approval in 2016 for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. The company also advanced HTX-019, an injectable emulsion formulation of aprepitant, which obtained FDA approval as the first non-polyethylene glycol formulation for acute CINV prophylaxis in adults. The company’s most advanced pipeline candidate is HTX-011, an investigational, long-acting, non-opioid local anesthetic that combines bupivacaine and low-dose meloxicam. HTX-011 is designed to provide extended post-operative analgesia and has been evaluated in Phase III trials across multiple surgical settings. In addition to HTX-011, Heron is developing other drug candidates to address various analgesic and supportive care needs and is exploring strategic collaborations to broaden the commercial reach of its portfolio. Founded in 2011 and headquartered in Redwood City, California, Heron Therapeutics completed its initial public offering in 2015 and is listed on Nasdaq under the ticker HRTX. The company primarily serves the U.S. market and is pursuing global partnerships to expand its geographic footprint. Heron’s leadership team comprises industry veterans with expertise in clinical development, regulatory affairs and commercialization, supporting the company’s mission to deliver innovative treatments that enhance patient care.AI Generated. May Contain Errors. Read More Heron Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreHRTX MarketRank™: Heron Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 437th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingHeron Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialHeron Therapeutics has a consensus price target of $2.50, representing about 476.2% upside from its current price of $0.43.Amount of Analyst CoverageHeron Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Heron Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeron Therapeutics has a P/B Ratio of 6.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Heron Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.56% of the float of Heron Therapeutics has been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Heron Therapeutics has recently increased by 4.27%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentHeron Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Heron Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for HRTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows7 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.10% of the stock of Heron Therapeutics is held by insiders.Percentage Held by Institutions80.01% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Heron Therapeutics' insider trading history. Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HRTX Stock News HeadlinesIs Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?June 30, 2026 | finance.yahoo.comHeron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent DecisionJune 28, 2026 | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.July 6 at 1:00 AM | Porter & Company (Ad)Heron Therapeutics (HRTX) Receives a Buy from H.C. WainwrightJune 9, 2026 | theglobeandmail.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Heron Therapeutics (HRTX) and Praxis Precision Medicines (PRAX)June 6, 2026 | theglobeandmail.comHeron Therapeutics Appeals Ruling Invalidating CINVANTI PatentsJune 4, 2026 | theglobeandmail.comHeron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI PatentsJune 2, 2026 | finanznachrichten.deU.S. District Court Issues Decision Regarding CINVANTI® PatentsJune 2, 2026 | globenewswire.comSee More Headlines HRTX Stock Analysis - Frequently Asked Questions How have HRTX shares performed this year? Heron Therapeutics' stock was trading at $1.30 at the beginning of the year. Since then, HRTX stock has decreased by 66.6% and is now trading at $0.4339. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics, Inc. (NASDAQ:HRTX) posted its earnings results on Monday, May, 11th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The biotechnology company earned $34.71 million during the quarter, compared to the consensus estimate of $36.72 million. Heron Therapeutics had a negative net margin of 20.53% and a negative trailing twelve-month return on equity of 7,747.30%. Read the conference call transcript. Does Heron Therapeutics have any subsidiaries? Heron Therapeutics subsidiaries include Heron Therapeutics B.V.. How do I buy shares of Heron Therapeutics? Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Heron Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings5/11/2026Today7/06/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 HRTX's financial health is in the Red zone, according to TradeSmith. HRTX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRTX CIK818033 Webwww.herontx.com Phone(858) 251-4400Fax650-365-6490Employees300Year Founded1983Price Target and Rating Average Price Target for Heron Therapeutics$2.50 High Price Target$3.00 Low Price Target$2.00 Potential Upside/Downside+476.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.19 million Net Margins-20.53% Pretax Margin-20.53% Return on Equity-7,747.30% Return on Assets-8.94% Debt Debt-to-Equity Ratio17.51 Current Ratio2.53 Quick Ratio1.51 Sales & Book Value Annual Sales$154.90 million Price / Sales0.53 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book6.20Miscellaneous Outstanding Shares189,280,000Free Float177,733,000Market Cap$82.13 million OptionableOptionable Beta1.65 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:HRTX) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored“By July 30, Elon Musk’s Prophecy Will Fulfill Itself”Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
